Skye and Redx Merge Into Fibrx With $125M Behind It

Skye Bioscience has agreed to combine with privately held UK fibrosis biotech Redx Pharma to form a new public company called Fibrx Therapeutics, backed by $125 million in fresh financing, with Skye shares down 7.12% at 0.50 as of 19:59 GMT on 14 August 2026.

Skye Bioscience (SKYE) has agreed to combine with Redx Pharma, a privately held biotech focused on fibrotic disease, in a transaction that will create a new publicly traded company named Fibrx Therapeutics and bring $125 million of fresh financing with it. The structure is one the sector has leaned on repeatedly through this cycle: a listed company with a shell-like valuation, a private company with a pipeline, and a syndicate of investors willing to fund the combination rather than a conventional IPO.

The market's first read was not kind to existing holders. Skye shares were quoted at 0.50, down 7.12% from a previous close of 0.54, as of the last trade at 19:59 GMT on 14 August 2026 — a session in which the stock swung between 0.47 and 0.88. That intraday range is wider than the whole share price, which tells you most of what needs to be said about how a stock at this level trades when a structural deal lands: liquidity is thin, the news is complicated, and price discovery happens in lurches.

Why $125 million is the number that matters

For a company whose shares trade below a dollar, the financing is the story rather than the merger mechanics. A $125 million raise attached to the combined entity is materially larger than what a sub-dollar listed biotech could raise on its own account in a follow-on offering, and it is the reason the transaction exists in this shape. Reverse-merger structures of this kind are, in practice, financing events with a ticker attached: the private company gets a listing and a treasury, the listed company's shareholders get exposure to a new pipeline, and the new investors set the price at which everyone else is diluted.

That last point is the mechanical explanation for the share reaction. When a concurrent private placement is sized at multiples of a company's market presence, incumbent holders are typically left with a minority of the combined entity. Without the ownership split disclosed in the material available here, the size of that dilution cannot be quantified — but a fall of 7.12% on the day, against a broadly flat tape, is the market pricing the possibility rather than the certainty.

For context on that tape: the S&P 500 tracker (SPY) was at $776.12, down 0.23%; the Nasdaq 100 tracker (QQQ) at $730.59, down 0.20%; and the Dow tracker (DIA) at $536.63, down 0.24%, all as of the same 19:59 GMT timestamp. There was no risk-off wave to blame. The move in Skye was Skye's own.

Fibrosis as the therapeutic bet

Redx Pharma's focus on fibrotic disease places Fibrx in one of the more stubborn areas of drug development. Fibrosis — the pathological scarring of tissue that stiffens and eventually disables organs — underlies conditions across the lung, liver, kidney and skin. It is a large addressable problem with a thin history of approvals, which is precisely why capital keeps returning to it: the commercial prize for a mechanism that reverses rather than merely slows scarring is very large, and the graveyard of failed attempts keeps competition manageable.

Naming the combined company Fibrx rather than retaining either legacy brand is a signal in itself. It tells investors that the fibrosis franchise, not Skye's prior identity, is the asset being marketed. Renaming also resets the story for institutional buyers who screen on narrative as much as on data — a practical consideration when the new entity will need to attract coverage and index eligibility from a low base.

What the deal does not yet tell investors

Three items will determine whether the $125 million is well spent, and none of them are settled by the announcement alone.

• The ownership split. How much of Fibrx legacy Skye holders retain, and on what conversion terms, is the single most important number for anyone who owns the stock today.
• The lead clinical asset and its next readout. Fibrosis programs live or die on functional endpoints. The timing of the first meaningful data event under the new corporate roof sets the clock on the cash.
• Runway math. A $125 million treasury is substantial for a mid-stage program and thin for a broad pipeline. Whether Fibrx concentrates or spreads that money will define its risk profile.

As Fierce Biotech reported, the financing is designed to net $125 million for the new public company, which frames it as working capital for the fibrosis assets rather than as a payout to selling shareholders.

The structural trend behind the transaction

Deals of this shape have become one of the default routes to a public listing for European private biotechs. Redx is a privately held company gaining a US-listed vehicle without running a traditional IPO process — avoiding the roadshow, the pricing risk and the timing dependency on a receptive window. In exchange, it accepts a valuation negotiated with a small group of crossover investors rather than set by a broad book.

For the listed side, the calculation is different. A company trading at half a dollar has limited independent options: it can cut costs and wait, sell itself, or find a partner with a pipeline that justifies re-rating the shell. The third path preserves the listing and gives shareholders optionality, but it hands control of the narrative — and usually the board and management — to the incoming asset. Existing holders are, in effect, being asked to swap a small claim on one story for a smaller claim on a better-funded one.

What to watch from here

The near-term checkpoints are procedural but consequential. Shareholder approval of the combination, the definitive share-exchange ratio, the closing of the financing tranche, and the ticker and exchange arrangements for Fibrx will each be disclosed before the deal completes. Any gap between the announced $125 million and the amount actually funded at closing would be the clearest early warning sign; conversely, an upsized round would indicate the syndicate likes what it saw in the fibrosis data room.

Beyond that, the test is scientific. Fibrosis has repeatedly punished companies that entered with strong preclinical narratives and left with equivocal biopsy or lung-function results. The $125 million buys Fibrx the right to run that experiment properly. It does not buy the answer.

Key facts

• SKYE share price: 0.50, down 7.12% (as of 19:59 GMT, 14 Aug 2026)
• Financing to new company: $125 million net
• New entity name: Fibrx Therapeutics
• SKYE day range: 0.47 – 0.88

Frequently asked questions

What exactly did Skye Bioscience announce?

Skye Bioscience entered an agreement to combine with Redx Pharma, a privately held biotech focused on fibrotic disease. The combination will create a new publicly traded company called Fibrx Therapeutics, and the transaction is accompanied by financing that will net $125 million for the new company to advance its fibrosis assets.

How did Skye shares react to the news?

Skye shares traded at 0.50 as of the last trade at 19:59 GMT on 14 August 2026, down 7.12% from the previous close of 0.54. The stock ranged between 0.47 and 0.88 during the session, an unusually wide swing that reflects thin liquidity in a sub-dollar listing digesting a complex structural deal.

What is Redx Pharma?

Redx Pharma is a privately held biotech company developing treatments for fibrotic disease. Through the combination with Skye Bioscience it gains access to a public listing and a funded treasury without running a conventional initial public offering process, an increasingly common route for private drug developers.

Why is fibrosis considered an attractive target area?

Fibrosis is the pathological scarring of tissue that stiffens and progressively disables organs including the lung, liver, kidney and skin. It affects large patient populations but has produced few approved therapies, so the commercial reward for a drug that halts or reverses scarring is substantial relative to the competition.

What is still unknown about the transaction?

The announcement as reported does not settle the ownership split between legacy Skye holders and Redx shareholders, the identity and timing of the lead clinical asset's next data readout, or how the $125 million will be allocated across programs. Each of those will materially affect the value of the combined company.

How did the broader market trade on the same day?

Major benchmarks were slightly lower and broadly flat. The S&P 500 tracker SPY stood at $776.12, down 0.23%; the Nasdaq 100 tracker QQQ at $730.59, down 0.20%; and the Dow tracker DIA at $536.63, down 0.24%, all as of 19:59 GMT on 14 August 2026. Skye's decline was company-specific.

Sources

• Skye and Redx form new entity with $125M to advance fibrosis assets — Fierce Biotech

Photo: Thirdman · Pexels Licence — source